[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573414":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":11,"id":44,"slug":11,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Epigenic Therapeutics, Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EPI-003","EXPERIMENTAL",null,[13],"Drug: EPI-003",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Intravenous (IV) infusion.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Feng Epigenic Therapeutics Clinical Trials","CONTACT","86-17621694653","clinical@epigenictx.com",[26],{"facility":27,"status":11,"city":28,"state":11,"zip":11,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Renji Hospital, Shanghai Jiao Tong University School of Medicine","Shanghai","China","CN",{"type":32,"coordinates":33},"Point",[34,35],121.45806,31.22222,{"lat":35,"lon":34},[38],{"name":39,"role":22,"phone":40,"phoneExt":11,"email":41},"YANG","+86 18201797677","yang_taihua@126.com",{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100573414",false,"NCT06745973","An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B","Inclusion Criteria:\n\n1. Be between 18 and 65 years of age, inclusive, at the time of signing the informed consent form;\n2. Confirmed diagnosis of CHB;\n3. Received a stable dose of NA therapy for ≥ 6 months prior to screening and plan to continue receiving the same dose for the duration of the study\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of liver cancer or cirrhosis;\n2. Combination of other major diseases; 3 Pregnant or lactating females.","ALL","18 Years","65 Years",{"count":53,"type":54},20,"ESTIMATED","INTERVENTIONAL",[57],"EARLY_PHASE1","This study is an open-label, 2-Part (Single Ascending Dose \\[Part 1\\] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB). EPI-003 is a liver-targeted antiviral therapeutic for intravenous (IV) injection that is capable of precise epigenetic modifications of the HBV genome without causing mutations in the gene sequence itself.",[60],"Chronic Hepatitis B","NOT_YET_RECRUITING","2024-12-18",{"date":64,"type":65},"2024-12-24","ACTUAL",{"date":67,"type":54},"2024-12-20",{"date":69,"type":54},"2026-12-31",{"name":5,"class":6},1]